Sign In
Buy JNJ
$239.08
+7.79 (+3.37%)
At Close: Jun 23, 2026
The Smartest Dividend Stocks to Buy With $5,000 Right Now
09:41pm, Tuesday, 13'th May 2025
If you have some spare cash, it's a great idea to put it into some dividend-paying stocks. They're a useful source of passive income that can help supplement your earned income.
Johnson & Johnson (JNJ) BofA Securities 2025 Healthcare Conference Transcript
02:51pm, Tuesday, 13'th May 2025
Johnson & Johnson (NYSE:JNJ ) BofA Securities 2025 Healthcare Conference May 13, 2025 1:40 PM ET Company Participants John Reed - Executive Vice President, Innovative Medicine, R&D Conference Call Par
50 Fortune World's Most Admired Companies (FWMAC): 24 "Safer", 1 Ideal Buy
06:25pm, Monday, 12'th May 2025
Fortune and Korn Ferry's survey identified the top 50 Most Admired Companies, focusing on criteria like investment value, management quality, and social responsibility. Four dividend-paying companies,
Johnson & Johnson: For Those Who Want Some Immunity Against Tariff Changes
03:35pm, Monday, 12'th May 2025
The U.S. and China have agreed to reduce tariffs temporarily for 90 days. I expect continued market volatility in the negotiation process. Johnson & Johnson could offer some immunity due to the specif
Drugmakers are spared worst-case drug pricing scenario for now
01:14pm, Monday, 12'th May 2025
Executive order says if companies and the government don't align on tying U.S. drug prices to other countries, the administration will impose its own plan.
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
12:36pm, Monday, 12'th May 2025
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
12:30pm, Monday, 12'th May 2025
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t
Pharma Stocks Hit by Trump's Vow to Cut US Prescription Drug Costs
10:41am, Monday, 12'th May 2025
The price cuts would see that U.S. consumers pay the same amount as the nation that pays the lowest price for that drug.
J&J Oral Psoriasis Drug Meets Primary Goal in Late-Stage Study
09:15am, Monday, 12'th May 2025
Data from a late-stage study shows that treatment with JNJ's icotrokinra helps achieve significant skin clearance in hard-to-treat scalp and genital psoriasis.
Fortress Dividends: 2 Of The Best All-Weather Income Stocks Built To Last
07:30am, Sunday, 11'th May 2025
Market turmoil often triggers a rush to 'safe' assets, but I believe these moments are best for buying cyclical stocks with strong upside potential. Rather than chasing what's popular, I focus on all-
Final Trade: SLV, JNJ, HYG, GOOGL
06:25pm, Friday, 09'th May 2025
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
5 Dividend ETFs to Buy and Hold for a Lifetime of Passive Income
03:32pm, Friday, 09'th May 2025
Dividend stock investing offers a reliable path to passive income and long-term wealth creation, making it a cornerstone for many portfolios. By owning shares in companies that pay regular dividends,
J&J's skin disease drug meets main goal in late-stage study
08:14am, Friday, 09'th May 2025
Johnson & Johnson said on Friday its experimental psoriasis drug met the main goal in a late-stage study on patients 12 years and older.
Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis
08:05am, Friday, 09'th May 2025
66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almost clear skin at Week 16 Icotrokinra continues to demon
4 High-Yielding Dogs of the Dow Are Crushing the Major Indices
07:13am, Friday, 09'th May 2025
Investors love dividend stocks, especially high-yield ones, because they offer significant income streams and have substantial total return potential.
